Cargando…
In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
Most antiretroviral medical treatments were developed and tested principally on HIV-1 B nonrecombinant strain, which represents less than 10% of the worldwide HIV-1-infected population. HIV-1 circulating recombinant form CRF02_AG is prevalent in West Africa and is becoming more frequent in other cou...
Autores principales: | Ni, Xiaoju, Abdel-Azeim, Safwat, Laine, Elodie, Arora, Rohit, Osemwota, Osamuede, Marcelin, Anne-Geneviève, Calvez, Vincent, Mouscadet, Jean-François, Tchertanov, Luba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398581/ https://www.ncbi.nlm.nih.gov/pubmed/22829822 http://dx.doi.org/10.1155/2012/548657 |
Ejemplares similares
-
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
por: Delelis, Olivier, et al.
Publicado: (2009) -
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017) -
Integrase and integration: biochemical activities of HIV-1 integrase
por: Delelis, Olivier, et al.
Publicado: (2008) -
Consensus Integrase of a New HIV-1 Genetic Variant CRF63_02A1
por: Agapkina, Y. Y., et al.
Publicado: (2019) -
A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles
por: Delelis, Olivier, et al.
Publicado: (2005)